Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML
The Lancet Haematology in conversation with - Un podcast de The Lancet Group
Catégories:
Professor Johannes Schetelig joins us to discuss the results of the ASAP phase 3 trial comparing remission induction with immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00065-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/...
